SYNFACTS Welcomes New Editorial Board Member Dr. Antonia Stepan
On June 1, 2022, Dr. Antonia Stepan from F. Hoffmann-La Roche Ltd (Switzerland) has joined the Editorial Board of SYNFACTS as responsible Editor for “Innovative Drug Discovery and Development”. Articles in this area were previously published in the categories “Synthesis of Natural Products and Potential Drugs” and “Chemistry in Medicine and Biology”.
Antonia Stepan studied chemistry at the University of Heidelberg (Germany) and the ETH Zurich (Switzerland) finishing with a diploma degree under the guidance of Prof. Erick Carreira. She obtained her PhD in 2006 from the University of Cambridge (UK) under the supervision of Prof. Steven V. Ley, CBE. She then moved to the lab of K. C. Nicolaou at Scripps (USA) for postdoctoral research (2006–2008). Before joining Roche as a Section Head, Medicinal Chemistry in 2018, Antonia worked at Boehringer Ingelheim (Germany) for one year and prior to that at Pfizer (USA) for almost nine years.
Detailed Profile
https://ch.linkedin.com/in/antonia-stepan-84931822
We are delighted to welcome Dr. Antonia Stepan on the SYNFACTS Editorial Board and look forward to a successful collaboration with her and her team of contributors from industry and academia!
About SYNFACTS
In SYNFACTS, current research results in chemical synthesis from the primary literature are screened, selected, evaluated, summarized, and enriched with personal comments by experts in their fields on a monthly basis.
